Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Upcoming Global Medical Conferences to Feature IRIDEX Proprietary MicroPulse™ Laser Therapy

Durable Clinical Effect, Substantial Economic Benefits Support Global Opportunity for Tissue-Sparing Solution

PR Newswire

MOUNTAIN VIEW, Calif., Sept. 26, 2013 /PRNewswire/ -- IRIDEX (Nasdaq: IRIX) today announced a number of key international conferences and workshops that will feature its proprietary MicroPulse Laser Therapy for the treatment of diabetes and glaucoma related disorders. 

The upcoming European Society of Retina Specialists (EURETINA) conference in Hamburg, Germany will feature an official Instructional Course on the use of IRIDEX' MicroPulse Therapy for retinal disorders such as those caused by complications of diabetes.  EURETINA is Europe's largest society of retina specialists. 

MicroPulse is a vision-preserving laser treatment that does not produce the retinal tissue damage that is often associated with traditional laser therapies.

"Independent, physician-sponsored inclusion within these influential conferences further validates our MicroPulse Laser Therapy, which we believe is well positioned for the current global trend toward value-based healthcare," said Will Moore, IRIDEX President and CEO. "The durable clinical effect combined with the substantial economic benefits for healthcare systems, support the global market opportunity available for our MicroPulse laser technology."

In addition, to address the comprehensive ophthalmologist opportunity in the emerging global markets for IRIDEX, there will be a company-sponsored satellite training meeting at the upcoming European Society of Cataract and Refractive Surgeons (ESCRS) conference.  ESCRS is Europe's leading organization for cataract and refractive surgeons.

The physician-led training will focus on clinical application of IRIDEX' MicroPulse technology as a single-versatile solution to address the needs of comprehensive ophthalmologists in both glaucoma and retina.

"With more than 1,400 global views of IRIDEX' most recent webinar, we are seeing strong interest from physicians in MicroPulse  Laser Therapy as a durable and economically appealing medical solution for both the glaucoma and retina markets," added Moore.

"Recent data regarding MicroPulse laser's effectiveness for patients suffering with glaucoma should prove to be a catalyst for ophthalmologists looking for a versatile solution for their retina, glaucoma, and comprehensive practices." 

The following links are to third party websites not affiliated with IRIDEX.  IRIDEX makes no representations as to the accuracy or completeness of any information contained therein:

Link to EURETINA Instructional Course – Retinal Applications http://www.euretina.org/hamburg2013/programme/instructional-courses.asp

Link to ESCRS Satellite Meeting – Glaucoma & Retinal Applications  http://www.escrs.org/amsterdam2013/satellite-meetings.asp

Link to Glaucoma Webinar for MicroPulse Laser Trabeculoplasty  - Glaucoma
http://eyetube.net/series/micropulse-educational-webinar/with-years-of-slt-data-why-consider-micropulse-sup-trade-sup-/

About MicroPulse Technology

MicroPulse is a tissue-sparing laser therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's MicroPulse technology and the Company's products relating thereto, including market adoption of these products and the performance of the technology; and trends in healthcare spending and healthcare systems. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012 and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 30, 2013 and June 29, 2013, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE IRIDEX

Latest News
Top News